Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. VZ
10. SPY

Go back to Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 8c

Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results

November 7, 2017 4:01 PM EST

WASHINGTON, Nov. 7, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the third quarter ended September 30, 2017.

"During the third quarter of 2017, Vanda demonstrated the importance of the diverse set of ongoing initiatives to advance our growth strategy," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "The tradipitant results in atopic dermatitis, early trends from the HETLIOZ to psychiatrists initiative and the resolution of the HETLIOZ pricing negotiation in Germany, all represent significant potential drivers of growth."

Key... More